Click here to close now.




















Welcome!

News Feed Item

Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

http://www.reportlinker.com/p02006104/Bleeding-Disorders-World-Pharmaceu...

Report Details

Treating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecasts

Treatments for bleeding - what're their prospects? Visiongain's new report gives you predictions for drugs controlling those blood clotting diseases. Stay ahead then. You discover financial results, technologies, R&D trends, opportunities, and forecasted revenues.

So you see what's possible for treating haemophilia (hemophilia) and other blood-coagulation disorders. Avoid missing out. You get data and analysis for that industry and market, assessing outlooks. You find business analysis, progress, and potential gains.

Hear what lies ahead for those products, benefiting your work and influence. Read on, then, to explore those medicines and see what their future could be worth.

Forecasts and other information explaining lucrative possibilities for treatments

Our study reveals trade predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides revenue forecasting from 2013 to 2024, that new work shows historical findings, growth rates, and market shares. There you get feel for commercial outlooks and developments (R&D). You also gain an interview, 50 charts, and 78 tables.

Futures of medicines stopping and preventing haemorrhaging - data to help your work

Our study concludes that, from 2014, patients, healthcare providers, and pharma companies will gain from that medical and technological progress. Hear what's possible.

Find there how you can help your research, analyses, and decisions. Also save time. And discover how you could benefit your authority through better understanding the future.

So the following sections explain what you get in our new investigation.

Forecasting of that world market and its main segments - see what's likely to happen

What's that industry's potential? What're the secrets of its progress? Discover in our report overall world revenue to 2024 for pharmaceuticals controlling bleeding.

Also you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:

• Haemophilia A

• Haemophilia B

• Thrombocytopenia

• Related diseases (other coagulation factor deficiencies, grouped).

How will those markets expand? Which classes of therapy will generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales. Also you assess products' futures.

Predicting of existing and expected therapies' revenues

Find sales outlooks for top brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for 10 marketed products, including these:

• Advate

• NovoSeven

• Kogenate

• BeneFIX

• FEIBA.

You also get revenue predictions for five expected agents, including these:• Rixubis• Eloctate• Alprolix.

There you find drugs and years with highest predicted sales rises. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and successes.

Our work also divides its overall prediction into geographical regions.

Healthcare in national markets - what outlooks for business?

In developed and developing countries, opportunities for providers of those products and technologies will occur from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:

United States (US)

Japan

Germany, France, UK, Italy, and Spain (EU5)

Brazil, Russia, India, and China (BRIC nations).

There you find places with highest revenues and potential sales growth. Our work explains. You assess international prospects for modifying bleeding control, preventing excessive blood loss, also appraising needs and demands.

Explore, too, how that haematological technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing issues.

Events and forces for developing, producing, marketing, and selling blood-stemming drugs

The report shows you issues and events affecting that industry from 2014, including these:

• Advances in understanding haemostasis and coagulation aiding science and product development

• Needle-free drug delivery and other innovations

• Synthetic purification processes and other novel techniques for making biologics and biosimilars

• Long-acting clotting factor therapy and recombinant coagulation factors

• Use of prophylactic schedules (prophylaxis) increasing

• Regulators, pricing, and other challenges - approvals, costs, and concerns.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Discover what the future holds.

Examine, then, what stimulates and restrains players in that industry and affects results.

Companies and overall 2017 market value - find outlook for success

What happens next? From 2014 new treatments there and improving healthcare in rising countries encourage investments, medical advances, and higher revenues.

So our report predicts the world drugs market for preventing haemorrhages will generate $13.5bn in 2017. There, large medical firms and biopharma specialists can win. See how.

In particular, then, you explore activities and prospects of these companies:

• Baxter

• Novo Nordisk

• Bayer

• Pfizer

• CSL Behring.

R&D in that industry holds strengths, and from 2014 there will arise many opportunities. This decade onwards, then, patients, payers, and companies will benefit.

And you discover how that market can perform, staying ahead in knowledge.

Ways Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 helps

In particular, our new investigation gives you these advantages:

• Revenues there to 2024 at world level, for 4 submarkets, and 15 products - assess outlooks for production, marketing, and sales

• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - examine developed and developing countries for potential revenues

• Prospects for established competitors, emerging companies, and new entrants - investigate portfolios, results, strategies, developmental activities, and successes.

Information found nowhere else, helping your searches, analyses, and decisions

Our new study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore commercial possibilities.

With that data you're less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort with our study, aiding your decisions.

You discover original insights then. So act now in advance of your rivals, also benefiting your authority.

1. Executive Summary

1.1 What This Report Covers1.2 Bleeding Disorders: World Pharma Industry and Market Overview 2013-20241.3 Chapter Outlines1.4 Research and Analysis Methods

2. Introduction to Bleeding Disorders

2.1 Understanding Haemostasis and Coagulation2.1.1 Vascular Spasm2.1.2 Platelet Activation and Aggregation2.1.3 Coagulation2.2 An Introduction to the Bleeding Disorders and Their Treatment2.2.1 Haemophilia A, B and C2.2.2 Von Willebrand Disease2.2.3 Thrombocytopenia

3. The World Pharmaceutical Market for Bleeding Disorders 2014-2024

3.1 The World Pharmaceutical Market for Bleeding Disorders in 20123.2 The Bleeding Disorders Pharmaceutical Market: An Overarching Revenue Forecast 2014-20243.3 The Pharmaceutical Market by Bleeding Disorder: Comparison of Revenue and Market Share, 2018 and 20243.4 The World Pharmaceutical Market for Bleeding Disorders by Therapeutic Subclass: Grouped Revenue Forecasts 2014-20243.5 Haemophilia A Accounted for Almost 70% of the Market in 20123.6 Haemophilia B Will See Increasing Prominence in the Bleeding Disorders Market3.7 Thrombocytopenia3.8 Other Coagulation Factor Deficiencies3.9 Summary of the Research and Analyses

4. Leading Drugs of the Market for Treating Bleeding Disorders, 2014-2024

4.1 The Leading Drugs for the Treatment of Bleeding Disorders in 20124.2 Leading Bleeding Disorder Drugs: Comparison of Revenue and Market Share, 2018 and 20244.3 Leading Bleeding Disorder Drugs: A Grouped Revenue Forecast, 2014-20244.4 Advate Will Continue to Dominate the Market4.5 NovoSeven: Patent Protection Has Expired, But Revenue Generation Remains Strong4.6 Kogenate: Needle-Free Delivery Makes it an Attractive Option for Patients4.7 BeneFIX Faces Competition in 2013 - How Will This Affect Revenue?4.8 FEIBA: The Original Treatment for Disease with Inhibitors4.9 ReFacto/ Xyntha: Produced Using an Entirely Synthetic Purification Process4.10 Helixate: Marketing Agreement With Bayer Extends Until 20174.11 Nplate: The Leading Product for Thrombocytopenia in 20124.12 Alphanate: A Staple Treatment for Bleeding Disorders Since 19784.13 Promacta Competes With Nplate, But Which Will Prove Most Successful?4.14 Promising Compounds in the Developmental Pipeline4.14.1 Rixubis: The First Recombinant FIX Treatment Factor for Routine Prophylaxis in Haemophilia B4.14.2 Eloctate: The First Long-Acting Clotting Factor Therapy for Haemophilia A?4.14.3 Alprolix: The First Long-Acting Clotting Factor Treatment for Haemophilia B?4.14.4 N8-GP: Novo Nordisk's Long Acting Compound for the Treatment of Haemophilia A4.14.5 N9-GP: Novo Nordisk's Long-Acting Treatment for Haemophilia B

5. The Leading National Pharmaceutical Markets for Bleeding Disorders, 2014-2024

5.1 The Leading National Markets for Bleeding Disorders: The US Dominates in 20125.2 The Leading National Markets: Comparison of Revenue and Market Share, 2018 and 20245.3 Leading National Pharmaceutical Markets for Bleeding Disorders: Grouped Revenue Forecasts, 2014-20245.4 The US Will Continue to Dominate the Bleeding Disorders Market Throughout the Forecast Period5.5 The EU5: What Prospects There?5.5.1 Germany Will Remain the Largest of the EU5 Markets5.5.2 France: Increasing Uptake of Prophylactic Therapy Will Drive Growth5.5.3 Italy: The 3rd Largest Market of the EU55.5.4 The UK: Well Developed Infrastructure for the Treatment of Bleeding Disorders5.5.5 Spain: Use of Recombinant Coagulation Factors is Relatively Low at Present5.6 Japan: Use of Prophylactic Treatment is Lower Than That of the Western World5.7 China: A Growing Domestic Bleeding Disorders Pharmaceutical Market5.8 Brazil: Baxter Will Be the Exclusive Provider of Recombinant Therapy for the Next 10 Years5.9 India: 90% of Patients Are Unable to Afford Treatment Costs5.10 Russia: Treatment Levels Per Capita Are High

6. Bleeding Disorders: R&D Pipelines, 2013

6.1 The R&D Pipeline for Bleeding Disorders: An Overview6.2 Four Candidates Are In Pre-Registration6.2.1 Novo Nordisk's NovoEight6.2.2 Novo Nordisk's NovoThirteen: Denied Approval by the FDA for the Second Time; Will It Be Third Time Lucky?6.2.3 Biogen Idec's Eloctate: The First Long-Acting Treatment for Haemophilia A?6.2.4 Biogen Idec's Alprolix: The First Long-Acting Treatment for Haemophilia B?6.3 The Phase III Development Pipeline: Novo Nordisk Has a Strong Presence6.3.1 Novo Nordisk's N8-GP and N9-GP: Second in Class Treatments?6.3.2 Baxter's rFVIIa BI6.3.3 Octapharma's Human-cl rhFVIII6.4 The Phase II/III Development Pipeline: An Abundance of Haemophilia A Treatments6.4.1 Baxter's BAX855: Another Long-Acting Haemophilia A Treatment6.4.2 Baxter has Purchased OBI-1 from Inspiration Biopharmaceuticals6.5 The Phase I/II Development Pipeline: Gene Therapy for Haemophilia B6.6 The Phase I Development Pipeline: Offerings from Novo Nordisk and Pfizer6.6.1 Novo Nordisk's mAb20216.6.2 Pfizer's PF-05280602

7. Leading Companies of the Bleeding Disorders Pharmaceutical Market

7.1 The Leading Companies of the Bleeding Disorders Pharmaceutical Market7.2 Baxter Accounted for Over 30% of the Bleeding Disorders Market in 2012, But Will It Remain Market Leader?7.3 Novo Nordisk: Demonstrating Commitment to Treating Bleeding Disorders7.4 Bayer: A Limited Product Portfolio?7.5 Pfizer: Declining Market Share During the Forecast Period?7.6 CSL Behring Has the largest Portfolio of Bleeding Disorder Drugs7.7 Grifols Will Have a Declining Market Share7.8 Amgen: Single Stake in the Bleeding Disorders Market7.9 Octapharma: Branching Into Recombinant Coagulation Factors7.10 GSK: Bleeding Disorders Are Not a Main Therapeutic Focus7.11 Biogen Idec: Market Entry Anticipated in 2014

8. Qualitative Analysis of the Bleeding Disorders Pharmaceutical Market, 2013-2024

8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 20138.1.1 Treatment of Bleeding is Essential8.1.2 The Threat of Generic/Biosimilar Competition is Low8.1.3 Advances in Technology Have Improved Treatment Options8.1.4 A Small Patient Population Ultimately Restricts the Market8.1.5 Emerging National Markets: Patients Often Having Little Access to Treatments8.1.6 High Barriers to Market Entry8.1.7 The Burden of Prophylactic Therapy8.2 The Opportunities and Threats Facing the Market, 2014-20248.2.1 Low Switch Rate Among Patients Receiving Treatment for Bleeding Disorders: An Opportunity and a Threat8.2.2 Demand for Treatment in the Emerging Markets is Increases, But Are Recombinant Therapies Too Expensive?8.2.3 High Barriers to Market Entry Will Limit Competition, But Also Limit Development8.3 Social, Technological, Economic and Political Forces Influencing the Bleeding Disorders Pharmaceutical Market, 2014-20248.3.1 Social Factors8.3.2 Technological Factors8.3.3 Economic Factors8.3.4 Political Factors

9. Research Interview

9.1 Interview With Dr Kamran Kamyar, M.D., Medical Manager, AryoGen Biopharma9.1.1 On the State of the Current Market9.1.2 On AryoGen's Presence in the Market9.1.3 On Important Developments in the Industry

10. Conclusions from Our Study

10.1 The World Pharmaceutical Market for Bleeding Disorders, 2014-202410.2 Bleeding Disorders: Leading Products on the Market, 2014-202410.3 Leading National Markets for the Bleeding Disorder Pharmaceutical Industry, 2014-202410.4 Trends in that Industry and Market10.4.1 Bleeding Disorders Are Serious Conditions Requiring Frequent Drug Treatment10.4.2 The Demand for Drug Treatment Is Increasing10.4.3 The R&D Pipeline is Well Stocked, But What Does This Mean for the Industry?

List of Tables

Table 1.1 Currency Exchange RatesTable 2.1 The Coagulation Factors: Compound Name, Associated Bleeding Disorder and Bleeding SeverityTable 2.2 Treatment for VWD: Drug, Mechanism of Action and Disease TypeTable 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Revenues ($m) and Market Shares (%), 2012Table 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024Table 3.3 The World Market by Bleeding Disorder: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024Table 3.4 The World Market for Bleeding Disorders by Disorder: Grouped Revenue ($m) and Market Share (%) Forecasts, 2013-2024Table 3.5 Haemophilia A: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 3.6 Haemophilia B: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 3.7 Thrombocytopenia: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 3.8 Other Coagulation Factor Deficiencies: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.1 The Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Revenues ($m) and Market Shares (%), 2012Table 4.2 The Leading Drugs for the Bleeding Disorders: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024Table 4.3 Leading Drugs: Grouped Revenue Forecasts ($m), 2013-2024Table 4.4 Advate: Key FactsTable 4.5 Advate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.6 NovoSeven: Key FactsTable 4.7 NovoSeven: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.8 Kogenate: Key FactsTable 4.9 Kogenate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.10 BeneFIX: Key FactsTable 4.11 BeneFIX: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.12 FEIBA: Key FactsTable 4.13 FEIBA: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.14 ReFacto/ Xyntha: Key FactsTable 4.15 ReFacto/ Xyntha: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.16 Helixate: Key FactsTable 4.17 Helixate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.18 Nplate: Key FactsTable 4.19 Nplate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.20 Alphanate: Key FactsTable 4.21 Alphanate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.22 Promacta: Key FactsTable 4.23 Promacta: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.24 Rixubis: Key FactsTable 4.25 Rixubis: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.26 Eloctate: Key FactsTable 4.27 Eloctate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.28 Alprolix: Key FactsTable 4.29 Alprolix: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.30 N8-GP: Key FactsTable 4.31 N8-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.32 N9-GP: Key FactsTable 4.33 N9-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.1 Leading National Markets for Bleeding Disorders: Revenues ($m) and Market Shares (%), 2012Table 5.2 The Leading National Markets: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024Table 5.3 The Leading National Markets for Bleeding Disorders: Grouped Revenue Forecasts ($m), 2013-2024Table 5.4 The US Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.5 The EU5 Bleeding Disorders Market by Country: Revenue ($m) and Market Share (%) Forecasts, 2013-2024Table 5.6 The German Bleeding Disorder Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.7 The French Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.8 The Italian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.9 The UK Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.10 The Spanish Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.11 The Japanese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.12 The Chinese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.13 The Brazilian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.14 The Indian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.15 The Russian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 6.1 Bleeding Disorders: Candidates in Pre-Registration, 2013Table 6.2 Bleeding Disorders: Candidates in Phase III Development, 2013Table 6.3 Bleeding Disorders: Candidates in Phase II/III Development, 2013Table 6.4 Bleeding Disorders: Candidates in Phase I/II Development, 2013Table 6.5 Bleeding Disorders: Candidates in Phase I Development, 2013Table 7.1 The Leading Companies of the Bleeding Disorders Market: Revenues ($m) and Market Shares (%), 2012Table 7.2 Baxter: Product Portfolio for Bleeding Disorders, 2013Table 7.3 Novo Nordisk: Bleeding Disorders Product Portfolio, 2013Table 7.4 Bayer: Bleeding Disorders Product Portfolio, 2013Table 7.5 Pfizer: Bleeding Disorders Product Portfolio, 2013Table 7.6 CSL Behring: Bleeding Disorders Product Portfolio, 2013Table 7.7 Grifols: Bleeding Disorders Product Portfolio, 2013Table 7.8 Amgen: Bleeding Disorders Product Portfolio, 2013Table 7.9 Octapharma: Bleeding Disorders Product Portfolio, 2013Table 7.10 GlaxoSmithKline: Bleeding Disorders Product Portfolio, 2013Table 7.11 Biogen Idec: Bleeding Disorders Product Portfolio, 2013Table 8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 2013Table 8.2 Opportunities and Threats Facing the Bleeding Disorders Pharmaceutical Market, 2013-2024Table 8.3 Social, Technological, Economic and Political Factors Influencing the Bleeding Disorders Market (STEP Analysis), 2013-2024

List of Figures

Figure 2.1 Diagram of the Coagulation CascadeFigure 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Market Shares (%), 2012Figure 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024Figure 3.3 The World Market by Bleeding Disorder: Market Shares (%), 2018Figure 3.4 The World Market by Bleeding Disorder: Market Shares (%), 2024Figure 3.5 Haemophilia A: Revenue Forecast ($m), 2013-2024Figure 3.6 The Haemophilia A Submarket: Driving and Restraining Factors, 2013Figure 3.7 Haemophilia B: Revenue Forecast ($m), 2013-2024Figure 3.8 The Haemophilia B Submarket: Driving and Restraining Factors, 2013Figure 3.9 Thrombocytopenia: Revenue Forecast ($m), 2013-2024Figure 3.10 The Thrombocytopenia Submarket: Driving and Restraining Factors, 2013Figure 3.11 Other Coagulation Factor Deficiencies: Revenue Forecast ($m), 2013-2024Figure 4.1 Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Market Shares (%), 2012Figure 4.2 Leading Drugs for Bleeding Disorders: Market Shares (%), 2018Figure 4.3 Leading Drugs for Bleeding Disorders: Market Shares (%), 2024Figure 4.4 Advate: Revenue Forecast ($m), 2013-2024Figure 4.5 NovoSeven: Revenue Forecast ($m), 2013-2024Figure 4.6 Kogenate: Revenue Forecast ($m), 2013-2024Figure 4.7 BeneFIX: Revenue Forecast ($m), 2013-2024Figure 4.8 FEIBA: Revenue Forecast ($m), 2013-2024Figure 4.9 ReFacto/ Xyntha: Revenue Forecast ($m), 2013-2024Figure 4.10 Helixate: Revenue Forecast ($m), 2013-2024Figure 4.11 Nplate: Revenue Forecast ($m), 2013-2024Figure 4.12 Alphanate: Revenue Forecast ($m), 2013-2024Figure 4.13 Promacta: Revenue Forecast ($m), 2013-2024Figure 4.14 Rixubis: Revenue Forecast ($m), 2013-2024Figure 4.15 Eloctate: Revenue Forecast ($m), 2013-2024Figure 4.16 Alprolix: Revenue Forecast ($m), 2013-2024Figure 4.17 N8-GP: Revenue Forecast ($m), 2013-2024Figure 4.18 N9-GP: Revenue Forecast ($m), 2013-2024Figure 5.1 Leading National Markets for Bleeding Disorders: Market Share (%), 2012Figure 5.2 Leading National Markets for Bleeding Disorders: Market Shares (%), 2018Figure 5.3 Leading National Markets for Bleeding Disorders: Market Share (%), 2024Figure 5.4 The US Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.5 The EU5 Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.6 The German Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.7 The French Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.8 The Italian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.9 The UK Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.10 The Spanish Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.11 The Japanese Bleeding Disorders Market: Revenue Forecast ($m) 2013-2024Figure 5.12 The Chinese Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.13 The Brazilian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.14 The Indian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.15 The Russian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 6.1 Overview of R&D Pipeline for Bleeding Disorders: Candidates Filed for Approval or in Phase III Trials, 2013Figure 7.1 Leading Companies of the Bleeding Disorders Market: Market Share (%), 2012Figure 10.1 The World Market for Bleeding Disorders by Disorder: Comparison of Revenues ($m), 2012-2024Figure 10.2 Leading Drugs of the Bleeding Disorders Market: Comparison of Revenues ($m), 2012, 2018 and 2024Figure 10.3 Leading National Markets for Bleeding Disorders: Comparison of Revenues ($m), 2012, 2018 and 2024

Companies Listed

AmgenAryoGen BiopharmaAsklepios BiopharmaceuticalsBaxterBayerBeijing Northland BiotechBiogen IdecBrazilian Ministry of HealthCanadian Haemophilia SocietyCangene CorporationCatalyst BiosciencesChatham TherapeuticsCSL BehringEisaiEmpresa Brasileira de Hemoderivadose BiotechnologiaEuropean Medicines Agency (EMA)Food and Drug Administration (US FDA)Genetics InstituteGlaxoSmithKline (GSK)Green Cross CorporationGrifols BiologicalsHaemophilia Centres of England, Scotland, Northern Ireland or WalesHaemophilia Treatment Centre Collaborative Network of China (HTCCNC)HaemophilialifeHemobrásInspiration BiopharmaceuticalsIpsen PharmaItalian Association of Haemophilia Centres (AICE)Johns Hopkins MedicineLigand PharmaceuticalsNational Health Service (NHS)National Heart, Lung and Blood InstituteNektar TherapeuticsNovo NordiskOctapharmaPfizerShenyang Sunshine Pharmaceutical Co.Spanish Haemophilia SocietySwedish Orphan BiovitrumUnited Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO)US Food and Drug Administration (FDA)World Federation of Haemophilia

To order this report: Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 http://www.reportlinker.com/p02006104/Bleeding-Disorders-World-Pharmaceutical-Industry-and-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...